These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8143220)

  • 41. Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillator devices.
    Echt DS; Gremillion ST; Lee JT; Roden DM; Murray KT; Borganelli M; Crawford DM; Stewart JR; Hammon JW
    J Cardiovasc Electrophysiol; 1994 Sep; 5(9):752-60. PubMed ID: 7827714
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of defibrillation safety margin in modern implantable cardioverter defibrillators after administration of amiodarone.
    Köbe J; Reinke F; Dechering DG; Breithardt G; Eckardt L
    Clin Res Cardiol; 2012 Mar; 101(3):185-90. PubMed ID: 22057653
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias.
    Nademanee K; Feld G; Hendrickson J; Singh PN; Singh BN
    Circulation; 1985 Sep; 72(3):555-64. PubMed ID: 4017207
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators.
    Lee CH; Nam GB; Park HG; Kim HY; Park KM; Kim J; Choi KJ; Kim YH
    Circ J; 2008 Jan; 72(1):102-5. PubMed ID: 18159108
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of antiarrhythmic drugs on epicardial defibrillation energy requirements and the rate of defibrillator discharges.
    Jung W; Manz M; Pfeiffer D; Tebbenjohanns J; Pizzulli L; Lüderitz B
    Pacing Clin Electrophysiol; 1993 Jan; 16(1 Pt 2):198-201. PubMed ID: 7681571
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of sotalol in twenty patients with cardiac arrhythmias.
    Latour Y; Dumont G; Brosseau A; LeLorier J
    Int J Clin Pharmacol Biopharm; 1977 Jun; 15(6):275-8. PubMed ID: 881280
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sotalol: Current Status and Expanding Indications.
    Singh BN
    J Cardiovasc Pharmacol Ther; 1999 Jan; 4(1):49-65. PubMed ID: 10684524
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical predictors of defibrillation energy requirements.
    Neuzner J; Bahawar H; Berkowitsch A; Michel U; Schlepper M; Pitschner HF
    Am J Cardiol; 1997 Jan; 79(2):205-6. PubMed ID: 9193027
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical experience with sotalol in patients with drug-refractory ventricular arrhythmias.
    Ruder MA; Ellis T; Lebsack C; Mead RH; Smith NA; Winkle RA
    J Am Coll Cardiol; 1989 Jan; 13(1):145-52. PubMed ID: 2909562
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antiarrhythmic actions of DL-sotalol in ventricular and supraventricular arrhythmias.
    Singh BN
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S75-90. PubMed ID: 1279313
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ibutilide Reduces Ventricular Defibrillation Threshold and Organizes Ventricular Fibrillation Activation in Canine Heart Failure Model.
    Zhang N; Luo Q; Jin Q; Han Y; Huang S; Wei Y; Lin C; Chen K; Shen W; Wu L
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):323-334. PubMed ID: 32297025
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Implantation of automatic defibrillators by means of video-thoracoscopy. Authors' experience].
    Obadia JF; Rescigno G; George M; Kirkorian G; Touboul P; Chassignolle JF
    Minerva Cardioangiol; 1994 May; 42(5):197-201. PubMed ID: 8090289
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sotalol: a new beta-adrenergic blocker for ventricular arrhythmias.
    Cavusoglu E; Frishman WH
    Prog Cardiovasc Dis; 1995; 37(6):423-40. PubMed ID: 7777671
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of chronic amiodarone therapy on defibrillation threshold.
    Jung W; Manz M; Pizzulli L; Pfeiffer D; Lüderitz B
    Am J Cardiol; 1992 Oct; 70(11):1023-7. PubMed ID: 1414899
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of drugs on defibrillation capacity.
    Dopp AL; Miller JM; Tisdale JE
    Drugs; 2008; 68(5):607-30. PubMed ID: 18370441
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of sotalol against reperfusion-induced arrhythmias in Sprague-Dawley and Wistar rats.
    Lamontagne D; Rochette L; Vermeulen M; Yamaguchi N; Nadeau R; De Champlain J
    Fundam Clin Pharmacol; 1989; 3(6):671-85. PubMed ID: 2613163
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of chronic amiodarone therapy on defibrillation energy requirements in humans.
    Pelosi F; Oral H; Kim MH; Sticherling C; Horwood L; Knight BP; Michaud GF; Morady F; Strickberger SA
    J Cardiovasc Electrophysiol; 2000 Jul; 11(7):736-40. PubMed ID: 10921789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Shortening the second phase duration of biphasic shocks: effects of class III antiarrhythmic drugs on defibrillation efficacy in humans.
    Merkely B; Lubiński A; Kiss O; Horkay F; Lewicka-Nowak E; Kempa M; Szabolcs Z; Nyikos G; Zima E; Swiatecka G; Gellér L
    J Cardiovasc Electrophysiol; 2001 Jul; 12(7):824-7. PubMed ID: 11469436
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements.
    Fain ES; Lee JT; Winkle RA
    Am Heart J; 1987 Jul; 114(1 Pt 1):8-17. PubMed ID: 3604876
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction of electrical heterogeneity impairs ventricular defibrillation: an effect specific to regional conduction velocity slowing.
    Ujhelyi MR; Sims JJ; Miller AW
    Circulation; 1999 Dec 21-28; 100(25):2534-40. PubMed ID: 10604892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.